GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (OTCPK:UCBJF) » Definitions » Net Intangibles Purchase And Sale

UCB (UCBJF) Net Intangibles Purchase And Sale : $-99 Mil (TTM As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is UCB Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

UCB's net Intangibles purchase and sale for the six months ended in Jun. 2024 was $-50 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Jun. 2024 was $-99 Mil.

UCB Net Intangibles Purchase And Sale Historical Data

The historical data trend for UCB's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Net Intangibles Purchase And Sale Chart

UCB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Intangibles Purchase And Sale
Get a 7-Day Free Trial Premium Member Only Premium Member Only -216.67 -113.14 -238.42 -126.06 -85.06

UCB Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.85 -73.09 -35.75 -49.07 -49.52

UCB Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of UCB's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (OTCPK:UCBJF) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
XBRU:ARGX XBRU:TUB XBRU:ONWD XBRU:HYL XBRU:ALEMS XBRU:BIOS XBRU:OXUR VRTX REGN ASX:CSL XKRX:207940 ALNY XKRX:068270 BNTX BGNE MRNA SMMT UTHR OCSE:GMAB XKRX:196170
Traded in Other Exchanges
UCBJY:USA UCBb:UK 0NZT:UK UNC:Germany UCB:Belgium UCB:Austria
Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
Website
https://www.ucb.com
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).